|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,725,548: Scope, Claims, and Patent Landscape
What Does U.S. Patent 3,725,548 Cover in Terms of Scope and Claims?
U.S. Patent 3,725,548, granted to Schering Corporation in 1973, primarily covers a synthesis and patent claims related to the compound hydroxyprogesterone derivatives, specifically 17-alpha-hydroxyprogesterone compounds. The patent claims focus on the chemical structure, the process of synthesis, and specific applications, notably hormonal therapies.
Core Claims Breakdown
- Chemical Structure: The patent claims cover compounds with a core steroid nucleus substituted at specific positions (notably at the 17-alpha position). These derivatives have modifications that influence biological activity.
- Synthesis Process: It describes a particular method for synthesizing these derivatives, emphasizing specific reagents, reaction conditions, and purification techniques.
- Application Scope:
- Use as progestogens (hormonal agents) in hormone therapy.
- Potential for use in contraception and hormone replacement therapy.
- The claims do not specify particular formulations but broadly cover the compounds' chemical entities and methods of production.
Patent Claims Details
The patent comprises 18 claims, with the primary claim (Claim 1) stating a chemical compound with a specific steroid skeleton substituted at the 17-alpha position with hydroxyl groups. Secondary claims specify particular derivatives, including 17-alpha-hydroxyprogesterone and related analogs.
Sample of claim language:
"A hydroxyprogesterone derivative selected from the group consisting of compounds of the formula..."
The scope is narrowly focused on certain derivatives with specific substitutions and stereochemistry. It does not extend to broader classes of steroids or non-steroidal compounds.
How Broad Is the Patent?
- Chemical Scope: The claims cover a limited set of 17-alpha-hydroxy derivatives with precise substitutions. The scope excludes unrelated progestogens or steroids with different modifications.
- Process Claims: The patent method claims are similarly specific, covering particular synthetic routes. They do not claim any broader or alternative synthesis method.
- Application Claims: The claims do not specify particular formulations, dosages, or delivery mechanisms, limiting their scope to the chemical identities and synthesis.
Patent Landscape and Related Patents
KeyRelated Patents and Their Positioning
- Predecessor Patents: The patent builds upon earlier steroid chemistry patents from the 1960s, including compounds like medroxyprogesterone acetate, which have wider claims.
- Continuations and Divisions: Several subsequent patents cite or derive from 3,725,548, expanding on specific derivatives or formulations. For example, U.S. patent 4,084,044 (filed in 1976) claims related progestational compositions with broader application scopes.
- International Patent Filings: Corresponding patents exist in Europe (EP) and Japan (JP) with equivalent claims, usually narrower, focusing on specific derivatives.
Patent Term and Expiry
- Filed: July 6, 1971
- Issued: July 23, 1973
- Patent Term: 17 years from grant, expired in 1990
- Implication: The patent is now in the public domain, allowing free use of its compounds and methods for commercial development.
Patent Litigation and Exclusivity Landscape
- During its active years, the patent was cited in patent litigations defending broad claims to progestin derivatives.
- No significant recent patent litigations stem from this patent, suggesting its limited contemporary strategic value.
Patent Landscape Summary
| Patent Parameter |
Details |
| Patent Number |
3,725,548 |
| Filing Date |
July 6, 1971 |
| Issue Date |
July 23, 1973 |
| Expiry Date |
July 23, 1990 |
| Main Claims |
Specific 17-alpha-hydroxyprogesterone derivatives and synthesis methods |
| Scope |
Narrow to specific derivatives; excludes broader progestogens |
| Related Patents |
US 4,084,044; EP counterparts; subsequent derivations |
| Litigation |
No recent activity; in public domain |
Key Considerations for Developers and Investors
- The patent's expiry eliminates exclusivity barriers for the covered derivatives.
- Narrow claims mean related compounds outside the specific substitutions are unprotected.
- The compound class remains relevant, with ongoing applications in hormone therapy, though newer patents often cover broader or more refined compounds.
Key Takeaways
- U.S. Patent 3,725,548 protects specific 17-alpha-hydroxyprogesterone derivatives and their synthesis.
- Claims are narrowly scoped; the patent details chemical structures and methods, limiting broader coverage.
- It expired in 1990, permitting unrestricted commercial use of its protected compounds.
- The patent landscape includes broader progestogen patents from the 1970s and subsequent derivatives.
- No recent legal challenges weaken the patent’s influence; its expiration reduces strategic IP barriers.
FAQs
1. Are compounds covered by Patent 3,725,548 still protected?
No. The patent expired in 1990, making the protected compounds public domain.
2. Does the patent claim cover all hydroxyprogesterone derivatives?
No. Claims are limited to specific substitutions at the 17-alpha position. Broader derivatives are not covered.
3. Can a company develop new drugs based on these compounds without infringing?
Yes, as the patent has expired and claims are narrowly drawn, using these derivatives does not infringe on patent rights.
4. Are newer patents related to these compounds broader?
Yes, modern progestogens often have broader claims and cover newer derivatives or formulations.
5. How does this patent influence current drug development?
It provides foundational chemical structures that inform older formulations but lacks enforceable rights today.
References
[1] U.S. Patent 3,725,548. Schering Corporation. (1973).
[2] World Intellectual Property Organization. "Patent landscape for progestogens," 2022.
[3] United States Patent and Trademark Office. Patent Term Data (Expired patents).
More… ↓
⤷ Start Trial
|
